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Abstract
IMPORTANCE Immigrants are at an increased risk for co-occurring mental health and substance
misuse symptoms; however, effective treatments are lacking.
OBJECTIVE To evaluate the effectiveness of the Integrated Intervention for Dual Problems and Early
Action (IIDEA) program compared with enhanced usual care.
DESIGN, SETTING, AND PARTICIPANTS This effectiveness randomized clinical trial was conducted
from September 2, 2014, to February 2, 2017, in 17 clinics or emergency departments and 24
community sites in Boston, Massachusetts, as well as in Madrid and Barcelona, Spain. Equal
randomization (1:1) in 2-person blocks was used, assigning participants to either the IIDEA treatment
group (n = 172) or the enhanced usual care control group (n = 169). Intent-to-treat analyses assessed
effectiveness, and post hoc analyses examined whether results varied by symptom severity or
treatment dose. Eligible participants were between 18 and 70 years of age, self-identified as Latino,
screened positive for co-occurring symptoms, and were not receiving specialty behavioral health
services.
INTERVENTIONS Participants were randomized to a 10-session IIDEA treatment or to enhanced
usual care.
MAINOUTCOMES ANDMEASURES Primary outcomes were changes in alcohol and drug misuse
and results of a urine test for drugmetabolites but not for alcohol misuse. Secondary outcomes were
symptoms of depression, generalized anxiety, posttraumatic stress disorder, and overall
mental health.
RESULTS In total, 341 participants were randomized to either the IIDEA treatment group (n = 172;
94 [54.7%] female, mean [SD] age, 33.5 [11.6] years) or the enhanced usual care control group
(n = 169; 80 [47.3%] female, mean [SD] age, 34.3 [11.8] years). No statistically significant effects of
IIDEA were found for primary drug and alcohol outcomes (ASI Lite–drug score: β = −0.02 [SE, 0.69;
P = .88; Cohen d, 0.00; 95% CI, −0.17 to 0.17]; ASI Lite–alcohol score: β = −0.01 [SE, 1.19; P = .66;
Cohen d, 0.00; 95% CI, −0.12 to 0.12]; urine drug test result: β = −0.36 [SE, 0.43; P = .50; OR, 0.70;
95% CI, 0.30-1.61]), but statistically significant effects were observed for secondary mental health
outcomes. The IIDEA treatment was effective in reducing depressive symptoms per the Patient
Health Questionnaire-9 score (β = −1.14; SE, 0.47; P = .02; Cohen d, 0.20 [95% CI, 0.04-0.36]),
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Abstract (continued)
posttraumatic stress disorder symptoms per the Posttraumatic Stress Disorder Checklist-5 score
(β = −3.23; SE, 1.59; P = .04; Cohen d, 0.25 [95% CI, 0.01-0.37]), and overall mental health
symptoms per the Hopkins Symptom Checklist-20 (β = −0.20; SE, 0.07; P = .01; Cohen d, 0.25 [95%
CI, 0.08-0.42]) and composite mental health (β = −3.70; SE, 1.75; P = .04; Cohen d, 0.19 [95% CI,
0.01-0.36]) scores at the 6-month follow-up. Exploratory analyses suggested that 6-month
treatment effects occurred for patients whose drugmisuse wasmoderate to severe at the baseline
assessment. Among patients withmoderate to severe substancemisuse, IIDEA substantially reduced
substance use per the urine test results (odds ratio, 0.25 [95% CI, 0.09-0.67]; P = .01). Treatment
dose showed small to large effect sizes by outcome.
CONCLUSIONSANDRELEVANCE The IIDEA treatment did not change drugmisuse but did improve
secondary mental health and substancemisuse outcomes for a heterogeneous population with
moderate to severe symptoms; this finding provides a path for treating Latino immigrants with
co-occurring mental health and substancemisuse symptoms.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02038855
JAMA Network Open. 2019;2(1):e186927.
Corrected on February 15, 2019. doi:10.1001/jamanetworkopen.2018.6927
Introduction
Immigrants in the United States, for example, are at risk for co-occurring mental health and
substancemisuse symptoms.1 However, we know little about whether treatments that are effective
for native-born populations are also helpful for foreign-born populations with co-occurring
symptoms. Patients with co-occurring symptoms havemore severe impairment; worse treatment
outcomes; higher morbidity and mortality; increased treatment costs; and greater risk for
homelessness, incarceration, and suicide than patients with either a mental health or substance
misuse disorder alone.2-4 Because less than half of individuals with co-occurring symptoms access
treatment,5 engagement of immigrants with co-occurring symptoms is a serious obstacle, given their
fears of deportation, high rates of uninsurance, linguistic barriers, and discrimination.6,7 Identifying
effective treatments for Spanish-speaking immigrants is particularly important, as Latino populations
(eg, people from predominantly Spanish-speaking countries in North, Central, or South America and
the Caribbean islands) are the largest and fastest-growing immigrant population in the United States8
and Spain,9 and they confront enormous barriers to accessing behavioral health treatments.10
Structural and institutional barriers6 mean that Latino individuals may be less likely to access
evidence-based practices11 or have poorer clinical outcomes than non-Latino individuals.12
The literature suggests that Latino immigrants with co-occurring symptoms could be well
served by an intervention that is appropriate for a heterogeneous population, requires limited
screening and resources, and is relevant to those with diverse symptom severity.13,14 Thus, we
developed the Integrated Intervention for Dual Problems and Early Action (IIDEA) program, a
cognitive-restructuring, mindfulness-based therapy that includes substance-craving reduction and
coping strategies, designed to provide culturally tailored and evidence-based care for Latino
populations with co-occurring symptoms. We assessed IIDEA’s effectiveness and compared it with
the effectiveness of enhanced usual care in reducing substancemisuse and improvingmental health
symptoms among Latino individuals with co-occurring mental health symptoms (depression,
anxiety, and trauma symptoms) and substancemisuse (use of drugs, alcohol, and prescription
medication for a purpose not consistent with medical or legal guidelines).15 We describe the results
of this multisite randomized clinical trial conducted in Spain (Madrid and Barcelona) and the United
States (Boston, Massachusetts). We hypothesized that patients who received the IIDEA program
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would show symptom reduction and a greater likelihood of substance use abstinence comparedwith
those receiving enhanced usual care.
Methods
StudyDesign
This effectiveness trial16 used equal randomization (1:1) to the IIDEA treatment or to enhanced usual
care and was conducted from September 2, 2014, to February 2, 2017, in 17 clinics or emergency
departments and 24 community sites in Boston, Madrid, and Barcelona. The trial protocol is available
in Supplement 1. This study followed the Consolidated Standards of Reporting Trials (CONSORT)
guidelines, including the checklist and diagram to track participants during the enrollment and trial
procedures (Figure). Human participation approval was obtained from the institutional review boards
of all 3 participating institutions (Massachusetts General Hospital, Vall d’Hebron University Hospital,
and Fundación Jimenez Diaz). All participants provided written informed consent.
Treatment consisted of 10 to 12 sessions, lasting 45 to 75minutes each, of the IIDEA cognitive
behavioral intervention, which was adapted for diverse Latino patients; details of the cultural
adaptation of IIDEA are included in eAppendix 2 in Supplement 2. Trained clinicians at the sites
delivered the treatment for 3 to 6months in person or by telephone, and the sessions were audio-
recorded for quality control. A care manager at the sites contacted the enhanced usual care group to
assess their symptoms, ensure safety, and assist with referrals. Patients in the enhanced usual care
group met with their primary care physician as usual, if they were in care. Research assistants, who
were blind to study randomization, assessed the outcomes (including results of a urine drug screen)
at 2, 4, 6, and 12 months after baseline between November 3, 2014, and February 28, 2017.
Participants received $30 (in the United States) or €25 (in Spain) for each assessment, and the
incentives increased to $50 (or €30) for the 6- and 12-month assessments. An independent advisory
board was consulted annually during the study period. For quality control purposes, data collection
supervisors (L.H., L.C., P.A., and A.V.) listened to the first 3 interviews for each research assistant and
Figure. CONSORT FlowDiagram
2284 Assessed for eligibility
172 Randomized to IIDEA
39 Withdrew
133 Received treatment (≥1 sessions)
89 Received treatment (≥6 sessions)
172 Had complete data per assessment
124 Completed ≥3 assessments
258 Had complete overall data
134 Completed ≥3 assessments
169 Randomized to Enhanced Usual Care
169 Had complete data per assessment
341 Randomized
1943 Excluded
1900 Did not meet inclusion
criteria
6 Declined to participate
37 Lost to follow-up before
randomization
IIDEA indicates Integrated Intervention for Dual
Problems and Early Action.
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a random 15% of the sample. Detailed information on the study design is in eFigure 1 and eAppendix
1 in Supplement 2.
Participants and Recruitment Sites
Bilingual (English and Spanish) study staff enrolled participants through direct contact in primary
care clinic waiting rooms, emergency departments, and Latino-serving community-based
organizations or through referrals by health care professionals or other participants. Wemet with
clinic- or community-based organization leaders and staff to present our study and tailor recruitment
to each site.
Eligible participants were 18 to 70 years of age, self-identified as Latino, screened positive for
co-occurring symptoms, and were not receiving or about to receive specialty behavioral health
services (ie, therapy sessions with a psychiatrist, psychologist, or social worker) in the previous 3
months or the upcomingmonth. Positive co-occurring screening symptoms included an affirmative
response to 2 questions about mental health and 2 about substance misuse on the AC-OK (AC
[Cherry and Dillon], OK [Oklahoma])17 screener, a 15-item questionnaire validated in Spanish. This
cutoff point provided 0.95 sensitivity, 0.62 specificity, and 0.90 area under the curve for mental
health as well as 0.68 sensitivity, 0.90 specificity, and 0.83 area under the curve for substance
misuse, when compared with validated screener measures.18 The same cutoff point provided 0.67
sensitivity and 0.74 specificity for screening co-occurring symptoms.
Potential participants were excluded if they lacked the capacity to consent (assessed by a
validated screener)19 or reported imminent suicidal ideation (assessed with the Paykel Suicide
Scale).20 Those excluded for suicidality were clinically assessed and referred to urgent care, with the
opportunity to rescreen after a 30-day period. When research assistants detected cognitive
impairment associated with intoxication or severe substance use during the screening and/or
assessments, they included a note in the data and reported the details to study supervisors. The
research team discussed possible referral for detoxification services at study supervision meetings
and followed each case to determine if the individual could potentially take part in the trial once
stabilized.
Randomization andMasking
A study investigator (B.L.C.) generated a stratified block-randomization scheme21 that assigned
eligible participants to the treatment or enhanced usual care groups in a 1:1 ratio for each 2-person
block. Stratified by recruitment site and then clinician, each patient had a 50% chance of being
assigned to the intervention condition. The project coordinator at each site (who was not involved in
data collection) randomized patients after obtaining informed consent and baseline assessment.
Research assistants, blinded to the study condition, administered the follow-up assessments. Care
managers and clinicians were not blinded.
EnhancedUsual Care and IIDEAGroups
Participants in the enhanced usual care group continued usual care with their primary care physician,
if available. A care manager contacted enhanced usual care participants once every 3 weeks during
the treatment period (5 calls within a 6-month period) to administer the same assessment used in
the treatment sessions. This monitoring ensured that participants were not deteriorating, or if they
were, the care manager assisted themwith referrals to mental health or social services.
The IIDEA intervention is a transdiagnostic manualized therapy that addresses elevatedmental
health symptoms and symptoms of drug, alcohol, and benzodiazepine misuse; in this trial, this
intervention was tailored specifically for Latino individuals. The intervention integrates cognitive
behavioral therapy, motivational interviewing, mindfulness practice, and cognitive restructuring. The
substancemisuse component includes strategies for reducing cravings, preventing relapse,
strengthening coping skills, and preventing HIV or risk for sexually transmitted infections. The IIDEA
treatment concludes with the creation of a self-care plan, practice of learned skills, and additional
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booster sessions if needed. In this trial, IIDEA treatment was conducted in the participant’s preferred
language (English or Spanish) and was offered at home if there were childcare or illness constraints.
Detailed information can be found in eAppendix 2 in Supplement 2.
Therapists and Treatment Fidelity
The intervention was delivered weekly or biweekly by clinicians with a master’s degree or higher
(psychiatry residents, psychologists, social workers, and counselors). Clinician training consisted of
50 hours of didactic instruction and role play. Supervisors rated the first 2 sessions and a random 15%
of the total sample of sessions on a standardized fidelity scale (eAppendix 2 in Supplement 2).
Clinician fidelity was 84.8%.Weekly telephone supervisor meetings facilitated case review and
treatment fidelity across the sites, with an interrater agreement of 94.6% among 9 supervisors
(eAppendix 2 in Supplement 2).
OutcomeMeasures
Primary outcome measures were changes in the drug (α = .84; score range, 0-1; cutoff score, >0.1)
and alcohol (α = .70; score range, 0-1; cutoff score, >0.1) components of the Addiction Severity Index
(ASI) Lite,22 which evaluates lifetime and past 30-day behaviors, as well as changes in urine drug test
findings (DrugCheck Nx; TransMed),23 which checks for a binary outcome of drug metabolites and
use of any 6 drug types (amphetamine, benzodiazepine, cocaine, methamphetamine, heroin, and
marijuana) but not for alcohol misuse. Secondary outcome measures were the Patient Health
Questionnaire (PHQ-9) (α = .85; score range, 0-27; cutoff score, >10) for depressive symptoms24; the
Generalized Anxiety Disorder Scale (GAD-7) (α = .86; score range, 0-21; cutoff score, >10)25 for
generalized anxiety symptoms; the Posttraumatic Stress Disorder (PTSD) Checklist (PCL-5) (α = .94;
score range, 0-80; cutoff score, >33)26 for PTSD symptoms; and the Hopkins Symptom Checklist
(HSCL-20) (α = .94; score range, 0-4; cutoff score, >1.5)27 for overall mental health symptoms. All of
these measures have been validated in both English and Spanish28,29 (eTable 1 in Supplement 2
provides a detailed description of each instrument).
We created a composite measure for substance use symptoms, using the Alcohol Use Disorders
Identification Test (α = .78; score range, 0-12),30 Drug Abuse Screening Test (α = .87; score range,
0-10),31 and selected items with high internal consistency from the Benzodiazepine Dependence
Questionnaire (α = .90; score range, 0-27)32 as well as a composite construct formental health, using
PHQ-9, GAD-7, and PCL-5. Each componentmeasurewas standardized to a scale of 0 to 100, and the
compositewas formed on the basis of theirmean. The cutoff scores formental healthwere 35 points
or higher and for substancemisuse 20 points or higher. We updated 2measures from the originally
registered protocol (eTable 1 in Supplement 2). We also collected demographic data and other social
and cultural characteristics of the participants for secondary analysis (eTable 1 in Supplement 2).
Statistical Analysis
The patient sample size (n = 360) was chosen to achieve adequate power to detect meaningful
effect sizes on the primary outcomes.33 The actual sample (n = 341) approximates the target sample
size with attrition. We used effect sizes from similar studies with Latino populations and a pilot
study34 to estimate the sample needed to have 80% power to detect substantial treatment effects.
Our primary analyses used intent-to-treat principles and focused on treatment effects at
intervention completion (at most, 6months after baseline). Effect sizes were calculated in themetric
of odds ratio (OR) for binary outcomes and in the metric of Cohen d for continuous outcomes. The
ORs were calculated as an exponent of the regression coefficient from the estimated logit model.
Approximate 95% CIs are reported here, assuming the regression coefficients are normally
distributed approximately.
The 4 postrandomization assessments were included inmultilevel mixedmodels. To account for
missing data or incomplete assessments, we usedmultiple imputations via chained equations
(eAppendix 3 and eTable 5 in Supplement 2).21 Themixedmodel included a term to account for linear
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change in outcomes, a different slope between 6-month and 12-month assessments, and a random
effect for intercept (eAppendix 4 in Supplement 2). Site was represented by dummy-coded variables,
with Boston as the reference category. The treatment group was dummy coded, with 1 for
intervention and 0 for control. Time of assessment was coded in months and centered at the
6-month assessment, yielding codes –4 for the 2-month, –2 for the 4-month, 0 for the 6-month, and
6 for the 12-month assessments. This coding allows the dummy-coded treatment effect to reflect
the contrast at 6months.
To account for possible deviation from the linear time trend at 12months, we included a variable
coded0 for the first 3 assessments and 6 for the final assessment.We testedwhether the differences
between control and intervention were attenuated over time. The hierarchical nature of multilevel
models and clustered robust SEs accounted for the longitudinal data structure and nonindependence
of patient outcomes nestedwithin clinicians or clinics. Because the randomization balances observed
and unobserved confounders, our main analysis controls for no further covariates. Even after
adjusting for possible confounders, we observed no differences from themain results. We examined
in post hoc analyses whether the treatment effect was stronger among those with moderate to
severe symptoms (compared with mild) at the baseline assessment (eFigure 2 in Supplement 2) and
among those who received sessions primarily by telephone (compared with in person).
We conducted additional prespecified analyses to determine whether the treatment effect on
symptom reduction varied by dose, defined as the number of intervention sessions patients
received. The dose variable was categorized as 0 (enhanced usual care control group and treatment
group with no sessions), 1 to 3 sessions (minimal intervention), or 4 or more sessions (adequate
intervention). Although these analyses no longer relied on randomization, they evaluated whether a
greater dose was associated with stronger benefits for 6-month outcomes. Statistical significance
was indicated by 2-sided P  .05 using 2-tailed t tests at α = .05. Analyses were conducted in Stata,
version 15 (StataCorp LLC).21
Results
Overall, 341 participants enrolled across the 3 participating institutions between September 2, 2014,
to May 27, 2016 (Figure).35 Participants were randomized to either the IIDEA treatment group
(n = 172, of whom 78 [45.3%] weremale and 94 [54.7%] were female, with a mean [SD] age of 33.5
[11.6] years) or the enhanced usual care control group (n = 169, of whom 89 [52.7%] were male and
80 [47.3%] were female, with a mean [SD] age of 34.3 [11.8] years). Participants originated from 17
countries (not including the United States or Spain) and had lived in the host countries from less than
1 year to more than 30 years. Of the 341 participants, 311 (91.2%) were Latino immigrants born
outside of the United States or Spain. Table 1 presents the sociodemographic and clinical
characteristics at baseline. No baseline differences were seen between the treatment and control
groups. More than 50 participants (31.4%) in each group had positive findings from urine drug tests
at baseline.
Of the 172 individuals enrolled in IIDEA, 89 (51.7%) attendedmore than 6 sessions (covering the
core elements), 44 (25.6%) attended 1 to 5 sessions, and 39 (22.7%) did not initiate treatment (0
sessions). Participants aged 35 years or older; with a high school diploma, General Educational
Development, or higher educational level; and with no children were substantially more likely to
complete treatment. Compared with participants who did not complete treatment at baseline, those
who completed had statistically significantly higher mental health symptoms on the HSCL-20
(t = 3.03; P = .003) and the Benzodiazepine Dependence Questionnaire (t = 2.85; P = .005).
Table 2 presents the results of the intent-to-treat analysis for primary and secondary outcomes.
With regard to the primary outcomes, no statistically significant treatment effects on substance use
were found at the 6-month follow-up (ASI Lite–drug score: β = −0.02 [SE, 0.69; P = .88; Cohen d,
0.00; 95% CI, −0.17 to 0.17]; ASI Lite–alcohol score: β = −0.01 [SE, 1.19; P = .66; Cohen d, 0.00; 95%
CI, −0.12 to 0.12]; urine drug test result: β = −0.36 [SE, 0.43; P = .50; OR, 0.70; 95% CI, 0.30-1.61]).
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Table 1. Baseline Characteristics of the Intent-to-Treat Population
Variable
IIDEA Treatment
Group (n = 172)
EUC Control
Group (n = 169)
Characteristics, No. (%)a
Study site location
Boston, Massachusetts 44 (25.6) 37 (21.9)
Madrid, Spain 41 (23.8) 43 (25.4)
Barcelona, Spain 87 (50.6) 89 (52.7)
Age
18-34 y 100 (58.1) 96 (56.8)
35-49 y 48 (27.9) 48 (28.4)
≥50 y 24 (14.0) 25 (14.8)
Sex
Male 78 (45.3) 89 (52.7)
Female 94 (54.7) 80 (47.3)
Race/ethnicity
White 29 (17.0) 31 (18.3)
Black 9 (5.3) 9 (5.3)
Indigenous/Native American 9 (5.3) 17 (10.1)
Latino/Caribbean 21 (12.3) 14 (8.3)
Mixed 103 (60.2) 98 (58.0)
Educational level
<High school diploma 68 (39.5) 63 (37.3)
≥High school diploma, GED, or vocational school 104 (60.5) 106 (62.7)
Total personal income before tax in past year
<US $15 000 142 (83.5) 149 (88.7)
≥US $15 000 28 (16.5) 19 (11.3)
Recruitment source
Primary care clinic 75 (43.6) 73 (43.2)
Community-based organization 40 (23.3) 38 (22.5)
Emergency department 10 (5.8) 9 (5.3)
Patient referral 47 (27.3) 49 (29.0)
Citizenship status (United States or Spain)
Noncitizen 78 (46.2) 69 (41.3)
Citizen 91 (53.8) 98 (58.7)
Sense of belonging
No 70 (40.9) 69 (41.3)
Yes 101 (59.1) 98 (58.7)
Time in United States or Spain, mean (SD), y 10.03 (8.61) 10.96 (8.76)
Home country visits in past 12 mo, mean (SD), No. 0.20 (0.46) 0.31 (0.58)
Measures outcome, mean (SD)b
Discrimination scale score 17.91 (8.20) 17.97 (7.75)
Ethnic identity scale score 9.44 (1.88) 9.49 (2.08)
Family conflict scale score 2.25 (2.01) 2.21 (1.91)
ASI Lite–drug score 0.04 (0.07) 0.05 (0.09)
ASI Lite–alcohol score 0.22 (0.21) 0.21 (0.17)
PHQ-9–depression score 10.88 (5.52) 10.96 (5.95)
GAD-7 score 8.53 (4.91) 8.65 (5.24)
PCL-5 score 27.19 (16.87) 25.73 (17.54)
HSCL-20 score 1.55 (0.78) 1.48 (0.82)
Mental health scorec 38.30 (19.46) 37.99 (20.63)
Substance use scorec 21.38 (14.26) 23.21 (14.78)
DAST-10 score 1.27 (2.14) 1.46 (2.46)
AUDIT-C score 5.20 (3.57) 5.60 (3.35)
BDEPQ score 2.13 (4.28) 2.11 (4.23)
Mindfulness scorec 3.75 (1.09) 3.78 (1.10)
(continued)
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No adverse effects were identified in any intervention cases. However, the analysis of secondary
outcomes showed that IIDEAwas effective in decreasing depressive symptoms per the PHQ-9 score
(β = −1.14; SE, 0.47; P = .02; Cohen d, 0.20; 95%CI, 0.04-0.36), PTSD symptoms per the PCL-5 score
(β = −3.23; SE, 1.59; P = .04; Cohen d, 0.25; 95%CI, 0.01-0.37), and overall mental health symptoms
per the HSCL-20 (β = −0.20; SE, 0.07; P = .01; Cohen d, 0.25; 95% CI, 0.08-0.42) and composite
mental health (β = −3.70; SE, 1.75; P = .04; Cohen d, 0.19; 95% CI, 0.01-0.36) scores at the 6-month
follow-up.
Table 3 reports results of exploratory analyses of whether intervention effects weremoderated
by baseline symptom severity. For thosewithmoderate to severe baseline substance use andmental
health symptoms, IIDEAwas effective in reducing substance use per the urine test result (OR, 0.25;
95% CI, 0.09-0.67; P = .01), depression per the PHQ-9 score (Cohen d, 0.38; 95% CI, 0.15-0.62;
P = .001), anxiety per the GAD-7 score (Cohen d, 0.34; 95% CI, 0.06-0.63; P = .02), PTSD per the
PCL-5 score (Cohen d, 0.37; 95% CI, 0.08-0.65; P = .01), and overall mental health (Cohen d, 0.44;
95% CI, 0.21-0.67; P < .001) symptoms, when compared with the enhanced usual care control
counterparts. The treatment effects on substance use and the urine test results at 6months were
statistically significantly larger for those withmoderate to severe baseline symptoms than those with
mild symptoms (ASI Lite—drug score: β = −4.71 [SE, 2.25; P = .04; Cohen d, 0.59; 95%CI, 0.04-1.13];
urine test result: β = −1.64 [SE, 0.47; P < .001; OR, −1.64; 95% CI, 0.07-0.49]). With regard to
secondary outcomes, reduction in mental health symptoms was also greater among participants
with moderate to severe mental health symptoms (PHQ-9 score: β = −2.28 [SE, 0.72; P = .001;
Cohen d, 0.40; 95% CI, 0.15-0.64]; GAD-7 score: β = −1.72 [SE, 0.78; P = .03; Cohen d, 0.34; 95% CI,
0.04-0.64]; PCL-5 score: β = −5.35 [SE, 2.71; P = .048; Cohen d, 0.31; 95% CI, 0.01-0.64]; HSCL-20
score: β = −0.31 [SE, 0.10; P = .003; Cohen d, 0.39; 95% CI, 0.14-0.63]), in contrast to those with
mild symptoms.
Table 1. Baseline Characteristics of the Intent-to-Treat Population (continued)
Variable
IIDEA Treatment
Group (n = 172)
EUC Control
Group (n = 169)
Positive urine test result, No. (%)d
No 118 (68.6) 116 (68.6)
Yes 54 (31.4) 53 (31.4)
Trauma exposure, No. (%)
No 15 (8.7) 13 (7.7)
Yes 157 (91.3) 156 (92.3)
Abbreviations: ASI, Addiction Severity Index (score range, 0-1); AUDIT, Alcohol Use Disorders Identification Test (score
range, 0-12); BDEPQ, Benzodiazepine Dependence Questionnaire (score range, 0-27); DAST, Drug Abuse Screening Test
(score range, 0-10); EUC, enhanced usual care; GAD, Generalized Anxiety Disorder (score range, 0-21); GED, General
Educational Diploma; HSCL, Hopkins Symptom Checklist (score range, 0-4); IIDEA, Integrated Intervention for Dual
Problems and Early Action; PCL, Posttraumatic Stress Disorder Checklist (score range, 0-80); PHQ, Patient Health
Questionnaire (score range, 0-27).
a Demographic and clinical characteristics are presented before the imputation of missing data for race/ethnicity (missing
1 observation), personal income (missing 3), citizenship status (missing 5), sense of belonging (missing 3), number of
years in United States or Spain (missing 33), and number of home country visits (missing 2). The followingmeasures are
missing 2 observations each: discrimination scale (score range, 9-54, with higher scores indicating more discrimination),
racial/ethnic identity scale (score range, 3-12, with higher scores indicating closer identificationwith others from the same
culture or ethnic/racial descent), and family conflict scale (score range, 0-8, with higher scores indicating more family
conflicts).
b Missing observations of baseline outcomes are list-wise deleted and SDs from the available data are reported. Mean
baseline responses remain almost the same with the imputed data, except that IIDEA participants have slightly higher
baseline HSCL-20 scores than the EUC participants in the imputed data. For all outcomes of substance use and mental
health measures, higher scores indicate more symptoms and higher severity level.
c Mental health and substance use score range: 0 to 100; mindfulness score range: 1 to 6.
d Positive urine test result shows a binary outcome of drugmetabolite and use of any of the 6 drug types (amphetamine,
benzodiazepine, cocaine, methamphetamine, heroin, andmarijuana), but it does not show alcohol misuse.
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Table 4 shows that an adequate dose (>4 sessions) was associated with decreasing drug use
(β = −1.37; SE, 0.67; P = .048; Cohen d, 0.17; 95% CI, 0.01- 0.33) and lowering the substance use
composite score (β = −4.04; SE, 1.19; P = .002; Cohen d, 0.28; 95% CI, 0.12-0.44). Compared with
those who received fewer than 4 sessions, participants who received 4 or more sessions also
improved their depressive symptoms per the PHQ-9 score (β = −1.70; SE, 0.65; P = .01; Cohen
d, 0.30; 95%CI, 0.07-0.52), anxiety per the GAD-7 score (β = −1.27; SE, 0.58; P = .04; Cohen d, 0.25;
95%CI, 0.03-0.48), and PTSD per the PCL-5 score (β = −4.90; SE, 2.11; P = .03; Cohen d, 0.29; 95%
CI, 0.04-0.53) as well as their HSCL-20 (β = −0.30; SE, 0.10; P = .01; Cohen d, 0.37; 95% CI,
0.13-0.62) and composite mental health (β = −6.38; SE, 2.29; P = .01; Cohen d, 0.32; 95% CI, 0.09-
0.54) scores. A sensitivity analysis suggested larger treatment effects for those who received 6 or
more sessions (eTable 2 in Supplement 2).
Compared with Boston patients, Barcelona patients had a statistically significantly lower GAD-7
score (t = −2.41; P = .02), PCL-5 score (t = −3.69; P < .001), and HSCL-20 score (t = −1.99; P = .047)
at 6-month follow-up after adjusting for baseline severity, whereasMadrid patients had similar scores
to those of Boston patients, except for PCL-5 score (t = −2.04; P = .04). Six-months after baseline,
Madrid and Barcelona patients were like those in Boston in substance use severity and urine test
results. No evidence of differential effectiveness by site was found, except for PHQ-9 score, in which
the intervention effect appeared to be smaller in theMadrid patients (eTable 3 in Supplement 2) than
in the Boston patients. The negative time coefficients suggest a decline in themental health
symptoms and alcohol use up to the 6-month follow-up for both IIDEA and enhanced usual care
groups over time.
Most IIDEA patients received the treatment in person (98 [73.7%] in person vs 35 [26.3%] by
telephone). In-person patients were more likely to experience improvement (eTable 4 in
Supplement 2). These results are robust for alternativemodeling strategies, estimationmethods, and
howmissing data were handled (eAppendix 4 in Supplement 2). In addition, the results remain
significant after Benjamini-Hochberg adjustment, assuming a false discovery rate of 0.15.
Table 2. Primary and Secondary Outcomes Evaluated at 6-Month Follow-up of the Intent-to-Treat Population
Characteristic
β (SE)
ASI Lite–
Drug Score a
ASI Lite–
Alcohol Score a
Positive Urine
Test Resultb
PHQ-9
Score
GAD-7
Score
PCL-5
Score
HSCL-20
Score
Mental Health
Score
Substance Use
Score
IIDEA −0.02 (0.69) −0.01 (1.19) −0.36 (0.43) −1.14 (0.47)c −0.61 (0.45) −3.23 (1.59) c −0.20 (0.07)d −3.70 (1.75) c −1.27 (1.09)
Timee −0.10 (0.16) −1.00 (0.34)d 0.02 (0.08) −0.40 (0.11)f −0.46 (0.09)f −1.45 (0.31)f −0.07 (0.01)f −1.82 (0.36)f −0.54 (0.26)c
IIDEA × time 0.10 (0.17) 0.51 (0.38) −0.06 (0.12) −0.03 (0.15) 0.14 (0.12) 0.55 (0.48) −0.00 (0.02) 0.41 (0.52) 0.08 (0.38)
(Time – t)g 0.07 (0.21) 1.01 (0.43)c −0.05 (0.11) 0.30 (0.16) 0.47 (0.13)f 1.15 (0.40)d 0.06 (0.02)d 1.60 (0.50)d 0.55 (0.33)
IIDEA × (time – t) −0.11 (0.26) −0.56 (0.51) 0.09 (0.18) 0.18 (0.20) −0.16 (0.17) −0.27 (0.61) 0.01 (0.03) −0.14 (0.68) −0.18 (0.52)
Madrid, Spain sitesh −0.28 (0.77) 0.41 (1.65) −0.44 (0.33) 0.02 (0.43) −0.25 (0.46) −2.60 (1.27) c −0.05 (0.08) −1.28 (1.62) 2.47 (1.29)
Barcelona,
Spain sites
−0.17 (0.60) −0.38 (0.81) −0.25 (0.34) −0.53 (0.39) −0.91 (0.38)c −4.11 (1.11)f −0.13 (0.06)c −3.14 (1.39)c 2.02 (0.88)c
Baseline outcome 0.57 (0.04)f 0.47 (0.04)f 2.86 (0.30)f 0.53 (0.04)f 0.49 (0.04)f 0.55 (0.04)f 0.49 (0.04)f 0.59 (0.04)f 0.51 (0.04)f
Constant 1.95 (0.78)c 6.89 (1.44)f −1.85 (0.38)f 2.66 (0.52)f 2.62 (0.49)f 8.92 (1.63)f 0.44 (0.08)f 8.46 (2.04)f 5.57 (1.27)f
Abbreviations: ASI, Addiction Severity Index (score range, 0-1); GAD, Generalized
Anxiety Disorder (score range, 0-21); HSCL, Hopkins Symptom Checklist (score range,
0-4); IIDEA, Integrated Intervention for Dual Problems and Early Action; PCL,
Posttraumatic Stress Disorder Checklist (score range, 0-80); PHQ, Patient Health
Questionnaire (score range, 0-27).
a ASI Lite–drug and ASI Lite–alcohol scores range from0 to 1, but participant scores on
these measures were rescaled to a range of 0 to 100 before regression analyses (ie,
multiplied by 100). This adjustment was made to ensure meaningful regression
estimates.
b Positive urine test result shows a binary outcome of drugmetabolite and use of any of
the 6 drug types (amphetamine, benzodiazepine, cocaine,methamphetamine, heroin,
andmarijuana), but it does not show alcohol misuse. Coefficients in terms of the log
odds are reported for binary outcome.
c P < .05.
d P < .01.
e Time is a continuous variable that equals to –4 for research assessment 2, –2 for
research assessment 2, 0 for research assessment 3, and 6 for research assessment 5.
f P < .001.
g Time – t is a continuous variable that equals to 6 for research assessment 5 and 0
otherwise; t denotes the time when treatment ends, which equals to 6.
h The reference group comprises patients in the enhanced usual care control group, and
the reference site is Boston, Massachusetts.
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Discussion
We evaluated IIDEA, a culturally tailored intervention that integrates the treatment of mental health
symptoms and substancemisuse for Latino immigrants with some level of co-occurring symptoms.
No IIDEA effect on the primary alcohol and drug outcomeswas found in the treatment group, but the
Table 3. Primary and Secondary Outcomes by Baseline Severity Level Evaluated at 6-Month Follow-up of the Intent-to-Treat Population
Characteristic
β (SE)
ASI Lite–
Drug Score
ASI Lite–
Alcohol Score
Positive Urine
Test Result
PHQ-9
Score
GAD-7
Score
PCL-5
Score
HSCL-20
Score
Mental Health
Score
Substance Use
Score
IIDEA referencea 0.53 (0.46) −0.22 (1.51) 0.25 (0.45) 0.10 (0.51) −0.00 (0.50) −0.93 (1.72) −0.05 (0.08) 0.90 (1.86) −0.83 (1.22)
IIDEA moderate to severe
at baselineb
−4.71 (2.25)c 2.27 (1.95) −1.64 (0.47)d −2.28 (0.72)e −1.72 (0.78)c −5.35 (2.71)c −0.31 (0.10)e −9.79 (2.97)d −1.48 (2.08)
Moderate to severe at
baseline
13.20 (1.58)d 10.22 (1.89)d 3.70 (0.38)d 6.18 (0.50)d 5.12 (0.50)d 18.84 (1.83)d 0.73 (0.09)d 23.31 (2.07)d 11.99 (1.61)d
Time −0.10 (0.16) −1.00 (0.34)e 0.02 (0.08) −0.40 (0.11)d −0.46 (0.09)d −1.45 (0.31)d −0.07 (0.01)d −1.82 (0.36)d −0.54 (0.26)c
IIDEA × time 0.10 (0.17) 0.51 (0.38) −0.06 (0.12) −0.03 (0.15) 0.14 (0.12) 0.55 (0.48) −0.00 (0.02) 0.41 (0.52) 0.08 (0.38)
(Time − t) 0.07 (0.21) 1.01 (0.43)c −0.05 (0.12) 0.30 (0.16) 0.47 (0.13)d 1.15 (0.40)e 0.06 (0.02)e 1.60 (0.50)e 0.55 (0.33)
IIDEA × (time − t) −0.11 (0.26) −0.56 (0.51) 0.09 (0.18) 0.18 (0.20) −0.16 (0.17) −0.27 (0.61) 0.01 (0.03) −0.14 (0.68) −0.18 (0.52)
Madrid, Spain sites −0.39 (0.97) −0.58 (2.68) −0.39 (0.32) 0.17 (0.47) −0.26 (0.51) −1.89 (1.45) −0.02 (0.10) −0.36 (1.97) 1.85 (1.81)
Barcelona, Spain sites −0.75 (0.67) −2.93 (1.46)c −0.20 (0.34) −1.00 (0.39)c −1.25 (0.39)e −6.11 (1.31)d −0.18 (0.07)c −5.50 (1.59)d 1.40 (1.23)
Constant 2.89 (0.71)d 11.36 (1.63)d −2.19 (0.40)d 5.32 (0.42)d 5.13 (0.38)d 17.60 (1.40)d 0.85 (0.09)d 19.70 (1.65)d 11.36 (1.18)d
Effect size (95% CI)f 0.52 (−0.06
to 1.1)
0.10 (−0.05 to
0.26)
0.25 (0.09 to
0.67)e
0.38 (0.15 to
0.62)e
0.34 (0.06 to
0.63)c
0.37 (0.08 to
0.65)c
0.44 (0.21 to
0.67)d
0.44 (0.18 to
0.71)e
0.16 (−0.10 to
0.41)
Abbreviations: ASI, Addiction Severity Index (score range, 0-1); GAD, Generalized
Anxiety Disorder (score range, 0-21); HSCL, Hopkins Symptom Checklist (score range,
0-4); IIDEA, Integrated Intervention for Dual Problems and Early Action; PCL,
Posttraumatic Stress Disorder Checklist (score range, 0-80); PHQ, Patient Health
Questionnaire (score range, 0-27).
a The reference is mild symptoms at baseline.
b Moderate to severe symptoms at baseline is a dummy-coded indicator that equals to 1
if baseline severity equals or exceeds themoderate symptoms of the outcome and to
0 if otherwise (eAppendix 4 in Supplement 2).
c P < .05.
d P < .001.
e P < .05.
f Effect sizes were calculated in themetric of odds ratio for binary outcomes and Cohen
d for continuous outcomes; approximate 95% CIs are reported here. For participants
with moderate to severe symptoms at baseline, the treatment effect size was derived
from themodel estimates for each outcome.
Table 4. Participation in IIDEA Treatment Evaluated at 6-Month Follow-upa
Characteristic
β (SE)
ASI Lite–
Drug Score
ASI Lite–
Alcohol Score
Positive Urine
Test Result
PHQ-9
Score
GAD-7
Score
PCL-5
Score
HSCL-20
Score
Mental Health
Score
Substance Use
Score
IIDEA patients with 0-3
sessions
1.44 (0.89) 2.74 (1.70) −0.19 (0.45) −0.70 (0.69) 0.55 (0.77) −0.80 (2.10) −0.01 (0.09) 0.14 (2.80) 3.47 (2.09)
IIDEA patients with ≥4
sessions
−1.37 (0.67)b −0.89 (1.38) −0.60 (0.52) −1.70 (0.65)b −1.27 (0.58)b −4.90 (2.11)b −0.30 (0.10)c −6.38 (2.29)c −4.04 (1.19)c
Madrid, Spain sitesd −1.27 (1.12) −1.14 (2.21) −0.40 (0.60) −0.24 (0.71) −0.45 (0.70) −2.34 (1.72) −0.02 (0.13) −1.97 (2.32) 1.39 (1.66)
Barcelona, Spain sites −1.39 (0.82) −0.28 (1.32) −0.53 (0.36) −1.52 (0.65)b −1.50 (0.39)e −5.73 (1.22)e −0.18 (0.10) −6.13 (1.62)e 0.12 (1.09)
Baseline outcome 0.61 (0.08)e 0.44 (0.05)e 2.28 (0.36)e 0.47 (0.05)e 0.46 (0.07)e 0.51 (0.06)e 0.49 (0.07)e 0.54 (0.06)e 0.54 (0.06)e
Intercept 1.77 (0.94) 6.39 (1.82)c −1.49 (0.33)e 3.64 (0.85)e 2.70 (0.73)e 9.29 (1.72)e 0.41 (0.14)c 10.18 (2.99)c 4.19 (1.79)b
Sample size, No.f 268 268 257 268 268 268 216 268 268
Effect size (95% CI)g 0.17 (0.01 to
0.33)
0.04 (−0.09 to
0.18)
0.60 (−0.42 to
1.62)
0.30 (0.07 to
0.52)
0.25 (0.03 to
0.48)
0.29 (0.04 to
0.53)
0.37 (0.13 to
0.62)
0.32 (0.09 to
0.54)
0.28 (0.12 to
0.44)
Abbreviations: ASI, Addiction Severity Index (score range, 0-1); GAD, Generalized
Anxiety Disorder (score range, 0-21); HSCL, Hopkins Symptom Checklist (score range,
0-4); IIDEA, Integrated Intervention for Dual Problems and Early Action; PCL,
Posttraumatic Stress Disorder Checklist (score range, 0-80); PHQ, Patient Health
Questionnaire (score range, 0-27).
a Missing data are list-wise deleted. The analytical sample for each regression slightly
varies because themissing data differ for each outcome.
b P < .05.
c P < .01.
d The reference group comprises patients in the enhanced usual care control group, and
the reference site is Boston, Massachusetts.
e P < .001.
f Sample size varies because of missing data in a specific estimation.
g Effect sizes were calculated in themetric of odds ratio for binary outcomes and Cohen
d for continuous outcomes. Odds ratios were calculated as an exponent of the
regression coefficient from the estimated logit model. Approximate 95% CIs are
reported here, assuming the regression coefficients are normally distributed
approximately.
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secondary and exploratory results were shown to be effective for mental health outcomes. Intent-to-
treat analyses documented IIDEA’s effectiveness for mental health outcomes, which were
considered secondary in this trial but are clinically important. With regard to the primary alcohol and
drug symptoms, evidence indicated that IIDEAwas not effective in personswho presentedwithmild
levels of co-occurring symptoms. Auxiliary analyses suggested that the baseline severity level and
treatment dose were associated with substantial treatment effects, including on substancemisuse.
Similar to previous cognitive behavioral therapy trials, this trial found a reduction in mental
health symptoms, with small to moderate effect sizes.36,37 Participants with mild symptoms were
overrepresented in this trial, as it was designed to address substance use andmental health
symptoms in nondiagnosed participants who were not seeking treatment. However, this distribution
of the sample maymask amoderate treatment effect for participants with moderate to severe
clinical symptoms. Those with moderate to severe symptomsmay benefit most from the IIDEA
intervention. Telephone calls to control patients to assess their symptomsmay have also had an
effect by activating patients to deal with their symptoms38 and consequently decreasing the
difference between the treatment and control groups. Relatedly, 19 control patients (11.2%) reported
accessing mental health services in 1 of the follow-up interviews. In an earlier stage of the trial, we
found that 12% of participants screened positive for moderate or severe co-occurring symptoms on
the AC-OK screener, suggesting that a clinically significant number of people could benefit
from IIDEA.
The IIDEA therapy requires 50 hours of training for clinicians to achieve competency, plus
ongoing supervision, suggesting that adaptations may be needed for low-resource environments.
However, adoption of the intervention by clinicians, once trained, was described anecdotally as high.
For instance, an adaptation of IIDEA is being used in Spain in a project for treating pregnant women
with substance use symptoms.
Engaging individuals with co-occurring symptoms in behavioral health care can be a challenge.
However, IIDEA therapists were successful in initiating treatment with 77.3% of the intervention
participants, who were not seeking care. More than half completed treatment, demonstrating good
acceptability. This rate is higher than in other studies.39,40 In line with previous findings, studies show
a lower probability of premature treatment termination when Latino individuals are ethnically and
linguistically matched with their therapist41 and when interventions are culturally adapted.42
Understanding co-occurring symptoms as a chronic disease may help inform the
conceptualization of treatments as requiring ongoingmaintenance. A higher number of sessions was
associated with a statistically significant effect size for reducing alcohol outcomes and a statistically
significantly higher effect size for reducing depressive symptoms.40 The IIDEA intervention could
also benefit from amaintenance component, to sustain clinical improvement and prevent relapse.43
Moderation analysis shows greater effectiveness among a low-income, recent immigrant
population, a group that usually receives few resources.44 For Latino individuals with co-occurring
symptoms, treatment in person appears more effective than treatment by telephone, likely because
of the difficulty of maintaining attention to mindfulness exercises and cognitive restructuring.45-47
A first in-person visit may be necessary to reduce cultural mistrust and establish rapport.45 Finally,
the sustainability of IIDEA should be further assessed, including barriers to implementation in
community sites that lack institutional funding and access to continued supervision.48
Strengths and Limitations
The study has several strengths, including a diverse group of Latino immigrants from 17 countries and
with varied characteristics and symptom levels. Scientific rigor was maintained, as 77% of patients
completed the 12-month follow-up and 75% completed at least 3 follow-up assessments. Study
results suggest that the IIDEA program is an acceptable and effective behavioral health treatment for
Latino immigrants with co-occurring symptoms whose symptoms were within the moderate-
to-severe range.
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The study also has several limitations.We did not conduct biological screens for alcohol because
of cost constraints, which diminished our ability to detect differences across groups. Disclosure
concerns could have also undermined drug assessments at baseline. Participants were more willing
to disclose their substance use symptoms to a trusted clinician over time.49
Conclusions
Although the IIDEA program did not change drugmisuse in a heterogeneous sample, it did improve
secondary mental health outcomes. This treatment may provide a path for treating Latino
immigrants with co-occurring symptoms with elevated or moderate-to-severe symptoms.
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